FOXO TECHNOLOGIES INC. ANNOUNCES RESTRUCTURING AND CAPITAL RAISING TRANSACTIONS AND APPOINTS SEAMUS LAGAN AS CHIEF EXECUTIVE OFFICER
11 déc. 2024 08h00 HE
|
FOXO Technologies Inc.
MINNEAPOLIS, MN, Dec. 11, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”) announces a series of restructuring and capital raising transactions which...
GRI Bio to Participate in the Virtual Investor Closing Bell Series
06 déc. 2024 08h35 HE
|
GRI Bio, Inc.
Live webcast on Thursday, December 12th at 4:00 PM ET LA JOLLA, CA, Dec. 06, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an...
FOXO TECHNOLOGIES INC. ANNOUNCES RESULTS OF SPECIAL MEETING OF SHAREHOLDERS
02 déc. 2024 08h00 HE
|
FOXO Technologies Inc.
MINNEAPOLIS, MN, Dec. 02, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”), announces results of its Special Meeting of its Shareholders that was held...
FOXO TECHNOLOGIES INC., CONFIRMS DETAILS OF SPECIAL MEETING OF SHAREHOLDERS ON NOVEMBER 29, 2024.
25 nov. 2024 11h15 HE
|
FOXO Technologies Inc.
MINNEAPOLIS, MN, Nov. 25, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”), will hold its previously announced Special Meeting of its Shareholders at...
FOXO TECHNOLOGIES INC., CONFIRMS DETAILS OF SPECIAL MEETING OF SHAREHOLDERS ON DECEMBER 29, 2024.
25 nov. 2024 08h00 HE
|
FOXO Technologies Inc.
MINNEAPOLIS, MN, Nov. 25, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”), will hold its previously announced Special Meeting of its Shareholders at...
FOXO TECHNOLOGIES INC.’S BOARD OF DIRECTORS ANNOUNCES SPECIAL MEETING OF SHAREHOLDERS
18 nov. 2024 08h30 HE
|
FOXO Technologies Inc.
MINNEAPOLIS, MN, Nov. 18, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”), will hold a Special Meeting of its Shareholders at 10.30am EST on Friday,...
GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis
14 nov. 2024 16h20 HE
|
GRI Bio, Inc.
$13.9 million in gross proceeds raised since the beginning of 2024 extending expected cash runway into mid Q1 2025 and through interim data readout from GRI-0621 Phase 2a biomarker study Topline...
GRI Bio to Present at the 22nd International Colloquium on Lung and Airway Fibrosis
07 oct. 2024 08h30 HE
|
GRI Bio, Inc.
LA JOLLA, CA, Oct. 07, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...
Sonnet BioTherapeutics Announces Launch of CEO Corner Platform
30 sept. 2024 09h00 HE
|
Sonnet BioTherapeutics Holdings, Inc.
CEO Corner segments to include additional discussion related to press releases, events, corporate updates and pipeline progress Provides interested parties the ability to ask questions and submit...
GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions
30 sept. 2024 08h30 HE
|
GRI Bio, Inc.
Company continues to advance an innovative pipeline of NKT cell regulators for the treatment of high-value inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA, Sept. 30, 2024 (GLOBE...